Connect Biopharma Holdings Ltd. (CNTB)
0.6282
-0.04
(-5.56%)
USD |
NASDAQ |
Nov 19, 16:00
0.6201
-0.01
(-1.29%)
Pre-Market: 20:00
Connect Biopharma Holdings Enterprise Value : 19.22M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 19.22M |
| November 18, 2026 | 21.47M |
| November 17, 2026 | 16.22M |
| November 16, 2026 | 20.12M |
| November 13, 2026 | 22.20M |
| November 12, 2026 | 21.48M |
| November 11, 2026 | 22.92M |
| November 10, 2026 | 22.51M |
| November 09, 2026 | 26.65M |
| November 06, 2026 | 25.34M |
| November 05, 2026 | 25.52M |
| November 04, 2026 | 28.49M |
| November 03, 2026 | 28.10M |
| November 02, 2026 | 28.28M |
| October 30, 2026 | 29.81M |
| October 29, 2026 | 31.83M |
| October 28, 2026 | 32.43M |
| October 27, 2026 | 32.26M |
| October 26, 2026 | 32.65M |
| October 23, 2026 | 27.64M |
| October 22, 2026 | 27.37M |
| October 21, 2026 | 29.56M |
| October 20, 2026 | 34.25M |
| October 19, 2026 | 35.75M |
| October 16, 2026 | 36.14M |
| Date | Value |
|---|---|
| October 15, 2026 | 36.14M |
| October 14, 2026 | 36.31M |
| October 13, 2026 | 36.90M |
| October 12, 2026 | 36.11M |
| October 09, 2026 | 33.93M |
| October 08, 2026 | 34.58M |
| October 07, 2026 | 38.48M |
| October 06, 2026 | 36.09M |
| October 05, 2026 | 35.63M |
| October 02, 2026 | 37.40M |
| October 01, 2026 | 40.61M |
| September 30, 2026 | 47.93M |
| September 29, 2026 | 31.58M |
| September 28, 2026 | 37.12M |
| September 25, 2026 | 37.12M |
| September 24, 2026 | 38.38M |
| September 23, 2026 | 36.49M |
| September 22, 2026 | 45.62M |
| September 21, 2026 | 52.24M |
| September 18, 2026 | 49.72M |
| September 17, 2026 | 50.35M |
| September 16, 2026 | 47.20M |
| September 15, 2026 | 42.79M |
| September 14, 2026 | 77.74M |
| September 11, 2026 | 97.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anavex Life Sciences Corp. | -56.45M |
| Vaxcyte, Inc. | 7.643B |
| Foghorn Therapeutics, Inc. | -5.621M |
| Caribou Biosciences, Inc. | -34.92M |
| Oncolytics Biotech, Inc. | 49.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.15M |
| Revenue (Quarterly) | 0.736M |
| Total Expenses (Quarterly) | 16.89M |
| EPS Diluted (Quarterly) | -0.2565 |
| Profit Margin (Quarterly) | -2.19K% |
| Earnings Yield | -182.1% |
| Normalized Earnings Yield | -182.08 |